MAIA demonstrates promising survival benefits with THIO and Libtayo combination therapy in a Phase 2 trial for non-small cell lung cancer.
Next-generation telomere-targeted agent meets immunotherapy:
MAIA Biotechnology's ateganosin (THIO) and Regeneron's PD-1 inhibitor, Libtayo (cemiplimab), are being evaluated in a Phase 2 clinical trial (THIO-101, NCT05208944). The companies entered into a clinical supply agreement in February 2021 and amended the agreement in December 2024, further solidifying their collaboration to expand the third-line treatment group. This trial focuses on patients with advanced non-small cell lung cancer (NSCLC) who have failed prior immune checkpoint inhibitor (ICI) therapy, and it is expected to provide an innovative alternative in a market with significant unmet needs.
Sequential combination therapy to overcome resistance:
THIO is a first-in-class small molecule that reverses the activity of telomerase in cancer cells, inducing telomere uncapping and genomic instability, ultimately leading to cell death. By administering low-dose THIO to attack cancer cells followed by Libtayo, the immune system can effectively recognize and target the cancer cells, overcoming existing resistance to immunotherapy. This demonstrates a synergistic mechanism that goes beyond simple monotherapy, restoring and amplifying the anti-cancer immune response.
Survival metrics improved by more than two-fold compared to standard treatment:
The recent results from the THIO-101 Phase 2 trial showed that the combination therapy achieved a median progression-free survival (mPFS) of 5.6 months in the third-line treatment group of NSCLC patients. This is more than two-fold higher than the 2.5 months observed with standard-of-care chemotherapy. The median overall survival (mOS) was also 17.8 months. Furthermore, most adverse events were Grade 1 or 2, demonstrating a favorable safety profile and suggesting that it could replace existing highly toxic chemotherapy regimens.
Large NSCLC market and commercialization roadmap:
The global NSCLC treatment market is estimated at $24 billion to $44 billion in 2026 and is expected to grow at a compound annual growth rate of approximately 10%, exceeding $50 billion in the 2030s. To capture this market, MAIA is preparing to initiate the subsequent Phase 3 trial, THIO-104 (NCT06908304), and is accelerating commercialization efforts. Libtayo has already received FDA approval as a first-line NSCLC treatment in 2021 and 2022, suggesting that the regulatory hurdles for the combination therapy will be relatively low.
Clinical progress and potential for expanded global partnerships:
THIO has received FDA orphan drug designation for various cancer types, including hepatocellular carcinoma, small cell lung cancer, and glioblastoma, demonstrating its unique value. The joint development with Regeneron helps reduce costs, which is a key factor in enhancing MAIA's financial stability. The successful entry into late-stage clinical trials and the acquisition of positive data will serve as an important catalyst for future large-scale licensing agreements and global commercialization partnerships with major pharmaceutical companies.
MAIA Biotechnology's THIO, in combination with Regeneron's Libtayo, has demonstrated superior efficacy in a Phase 2 trial (THIO-101) for the third-line treatment of NSCLC, achieving a mPFS of 5.6 months and a mOS of 17.8 months, compared to 2.5 months for Docetaxel, the standard-of-care chemotherapy. This is a key indicator that enhances the potential for long-term commercialization as a first-in-class therapy for patients with resistance to existing immune checkpoint inhibitors in the global NSCLC market, which is expected to reach up to $44 billion by 2026. Through the clinical supply partnership with Regeneron, MAIA is significantly reducing new drug development costs while securing independent global commercialization rights, minimizing financial risk and accelerating the entry into the subsequent Phase 3 trial (THIO-104). Given that THIO has already received FDA orphan drug designation for multiple indications, including hepatocellular carcinoma and small cell lung cancer, the positive data from this Phase 2 trial is expected to serve as a strong short-term catalyst for enhancing MAIA's corporate value in future large-scale technology transfer (licensing) and partnership negotiations with global pharmaceutical companies.
Source: ClinicalTrials.gov (api_ct)